Clinical Trial Results:
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination with Atezolizumab or Placebo in Patients with HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy
Summary
|
|
EudraCT number |
2020-002818-41 |
Trial protocol |
SI DE PT NO HU FI PL FR IT |
Global end of trial date |
19 Jun 2024
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
28 Jun 2025
|
First version publication date |
28 Jun 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MO42319
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04740918 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
F. Hoffmann-La Roche AG
|
||
Sponsor organisation address |
Grenzacherstrasse 124, Basel, Switzerland, CH-4058
|
||
Public contact |
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
|
||
Scientific contact |
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
19 Jun 2024
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
19 Jun 2024
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The main purpose of this study is to evaluate the efficacy of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo in participants with human epidermal growth factor receptor 2 (HER2)-positive and programmed death-ligand 1 (PD-L1) -positive locally advanced (LABC) or metastatic breast cancer (MBC).
|
||
Protection of trial subjects |
All study participants were required to read and sign an Informed Consent Form.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
07 Jun 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Australia: 1
|
||
Country: Number of subjects enrolled |
Brazil: 8
|
||
Country: Number of subjects enrolled |
Canada: 2
|
||
Country: Number of subjects enrolled |
China: 31
|
||
Country: Number of subjects enrolled |
Colombia: 2
|
||
Country: Number of subjects enrolled |
Korea, Republic of: 1
|
||
Country: Number of subjects enrolled |
Philippines: 5
|
||
Country: Number of subjects enrolled |
Poland: 4
|
||
Country: Number of subjects enrolled |
Russian Federation: 3
|
||
Country: Number of subjects enrolled |
Türkiye: 17
|
||
Country: Number of subjects enrolled |
United States: 1
|
||
Country: Number of subjects enrolled |
Spain: 2
|
||
Country: Number of subjects enrolled |
Finland: 2
|
||
Country: Number of subjects enrolled |
France: 1
|
||
Country: Number of subjects enrolled |
United Kingdom: 4
|
||
Country: Number of subjects enrolled |
Italy: 6
|
||
Country: Number of subjects enrolled |
Norway: 1
|
||
Country: Number of subjects enrolled |
Portugal: 3
|
||
Country: Number of subjects enrolled |
Croatia: 2
|
||
Worldwide total number of subjects |
96
|
||
EEA total number of subjects |
21
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
84
|
||
From 65 to 84 years |
11
|
||
85 years and over |
1
|
|
||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||
Recruitment details |
A total of 96 participants with HER2-positive and PD-L1-positive LABC or MBC took part in the study across 52 investigative sites in 19 countries from 07 June 2021 to 19 June 2024. | |||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||
Screening details |
Participants were randomized in 1:1 ratio to receive trastuzumab emtansine + placebo (Arm 1) or trastuzumab emtansine + atezolizumab (Arm 2). | |||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||||
Roles blinded |
Investigator, Monitor, Carer, Data analyst, Subject, Assessor | |||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||
Arm title
|
Trastuzumab Emtansine 3.6 mg + Placebo | |||||||||||||||||||||||||||
Arm description |
Participants received trastuzumab emtansine, 3.6 milligrams (mg), every 3 weeks (Q3W) as an intravenous (IV) infusion in combination with atezolizumab matching placebo, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor. | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||||||||
Dosage and administration details |
Atezolizumab matching placebo dose, Q3W as IV infusion.
|
|||||||||||||||||||||||||||
Investigational medicinal product name |
Trastuzumab Emtansine
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
RO5304020
|
|||||||||||||||||||||||||||
Other name |
Kadcyla
|
|||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||||||||
Dosage and administration details |
Trastuzumab Emtansine, 3.6 mg, Q3W as IV infusion.
|
|||||||||||||||||||||||||||
Arm title
|
Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg | |||||||||||||||||||||||||||
Arm description |
Participants received trastuzumab emtansine, 3.6 mg, Q3W as an IV infusion in combination with atezolizumab, 1200 mg, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor. | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Atezolizumab
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
RO5541267
|
|||||||||||||||||||||||||||
Other name |
Tecentriq, MPDL3280A
|
|||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||||||||
Dosage and administration details |
Atezolizumab, 1200 mg, Q3W as IV infusion.
|
|||||||||||||||||||||||||||
Investigational medicinal product name |
Trastuzumab Emtansine
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
RO5304020
|
|||||||||||||||||||||||||||
Other name |
Kadcyla
|
|||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||||||||
Dosage and administration details |
Trastuzumab Emtansine, 3.6 mg, Q3W as IV infusion.
|
|||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Trastuzumab Emtansine 3.6 mg + Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received trastuzumab emtansine, 3.6 milligrams (mg), every 3 weeks (Q3W) as an intravenous (IV) infusion in combination with atezolizumab matching placebo, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received trastuzumab emtansine, 3.6 mg, Q3W as an IV infusion in combination with atezolizumab, 1200 mg, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Trastuzumab Emtansine 3.6 mg + Placebo
|
||
Reporting group description |
Participants received trastuzumab emtansine, 3.6 milligrams (mg), every 3 weeks (Q3W) as an intravenous (IV) infusion in combination with atezolizumab matching placebo, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor. | ||
Reporting group title |
Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||
Reporting group description |
Participants received trastuzumab emtansine, 3.6 mg, Q3W as an IV infusion in combination with atezolizumab, 1200 mg, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor. | ||
Subject analysis set title |
Trastuzumab Emtansine 3.6 mg + Placebo
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Participants received trastuzumab emtansine, 3.6 mg, Q3W as an IV infusion in combination with atezolizumab matching placebo, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor.
|
||
Subject analysis set title |
Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Participants received trastuzumab emtansine, 3.6 mg, Q3W as an IV infusion in combination with atezolizumab, 1200 mg, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor.
|
|
|||||||||||||
End point title |
Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | ||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of documented disease progression (PD), as determined by the investigator according to RECIST v1.1 or death from any cause whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). Median PFS was calculated using the Kaplan-Meier (KM) methodology. Data for participants without PD or death from any cause as of the data cut-off date were censored at the time of the last tumor assessment. ITT population included all participants who were randomized in the study, whether they received any study medication.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Atezolizumab vs Placebo | ||||||||||||
Comparison groups |
Trastuzumab Emtansine 3.6 mg + Placebo v Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||||||||||||
Number of subjects included in analysis |
96
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[1] | ||||||||||||
P-value |
= 0.2876 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.75
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.44 | ||||||||||||
upper limit |
1.28 | ||||||||||||
Notes [1] - Stratified Analysis: Local hormonal status (estrogen receptors (ER) and/or progesterone receptor (PgR) positive vs. ER and PgR negative/unknown) and Disease status (visceral metastasis without brain metastasis vs. non-visceral metastasis only without brain metastasis [including locally advanced disease] vs. Brain metastasis). |
|
|||||||||||||
End point title |
Overall Survival (OS) | ||||||||||||
End point description |
OS was defined as the time from the first dose of study treatment to the time of death from any cause. Participants who are alive as of the data cut-off date of the analysis were censored at the last known date they were alive. Participants with no post-baseline information were censored at the date of randomization plus 1 day. Median OS was calculated using the KM methodology. ITT population included all participants who were randomized in the study, whether they received any study medication. 99999= median and 95% confidence interval (CI) was not estimable due to insufficient number of events. 9999=median and upper limit of 95% CI was not estimable due to insufficient number of events.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Atezolizumab vs Placebo | ||||||||||||
Comparison groups |
Trastuzumab Emtansine 3.6 mg + Placebo v Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||||||||||||
Number of subjects included in analysis |
96
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[2] | ||||||||||||
P-value |
= 0.5151 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.59
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.39 | ||||||||||||
upper limit |
6.43 | ||||||||||||
Notes [2] - Stratified Analysis: Local hormonal status (ER and/or PgR positive vs. ER and PgR negative/unknown) and Disease status (visceral metastasis without brain metastasis vs. non-visceral metastasis only without brain metastasis [including locally advanced disease] vs. Brain metastasis). |
|
|||||||||||||
End point title |
Objective Response Rate (ORR) | ||||||||||||
End point description |
ORR = percentage of participants with complete response (CR) or partial response (PR) on two consecutive assessments, at least 28 days apart, as determined by the investigator using RECIST v.1.1. CR = disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR = at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. Only participants with measurable disease at baseline were analyzed for this outcome measure. Participants without a post-baseline tumor assessment were considered non-responders. An estimate of the ORR and its 95% CI (Wilson score confidence interval) were calculated for each treatment arm. Subset ITT with measurable disease included all participants in the ITT with a measurable disease at baseline. ITT population included all participants who were randomized to the study, whether or not they received any study medication.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Atezolizumab vs Placebo | ||||||||||||
Comparison groups |
Trastuzumab Emtansine 3.6 mg + Placebo v Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||||||||||||
Number of subjects included in analysis |
94
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[3] | ||||||||||||
P-value |
= 0.724 | ||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
1.16
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.5 | ||||||||||||
upper limit |
2.7 | ||||||||||||
Notes [3] - Stratified Analysis: Local hormonal status (ER and/or PgR positive vs. ER and PgR negative/unknown) and Disease status (visceral metastasis without brain metastasis vs. non-visceral metastasis only without brain metastasis [including locally advanced disease] vs. Brain metastasis). |
|
|||||||||||||
End point title |
Duration of Response (DOR) | ||||||||||||
End point description |
DOR was calculated for participants who had a best OR of CR/PR. DOR=time from first occurrence of documented OR until time of documented PD/death from any cause, whichever occurs first as determined by investigator assessment using RECIST. CR= disappearance of all target lesions or any pathological lymph nodes (whether target/non-target) having a reduction in short axis to <10 mm. PR=at least a 30% decrease in the SOD of target lesions, taking as reference baseline SOD. PD=at least a 20% increase in the SOD of target lesions, taking as reference smallest sum on the study including baseline (nadir). In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm. Median DOR was calculated using KM methodology. Subset ITT with measurable disease=all participants in the ITT with a measurable disease at baseline. Number analyzed=participants with OR i.e responders. 99999=upper limit of 95%CI was not estimable due to insufficient number of events.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Atezolizumab vs Placebo | ||||||||||||
Comparison groups |
Trastuzumab Emtansine 3.6 mg + Placebo v Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||||||||||||
Number of subjects included in analysis |
48
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[4] | ||||||||||||
P-value |
= 0.3531 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.65
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.26 | ||||||||||||
upper limit |
1.61 | ||||||||||||
Notes [4] - Stratified Analysis: Local hormonal status (ER and/or PgR positive vs. ER and PgR negative/unknown) and Disease status (visceral metastasis without brain metastasis vs. non-visceral metastasis only without brain metastasis [including locally advanced disease] vs. Brain metastasis). |
|
|||||||||||||
End point title |
PFS in Participants With Baseline Brain Metastases as Determined by Investigator Assessment Using RECIST v1.1 | ||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Median PFS was calculated using the KM methodology. ITT with brain metastasis population included all participants in ITT with brain metastasis at randomization. 99999=upper limit of 95% CI was not estimable due to insufficient number of events.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Atezolizumab vs Placebo | ||||||||||||
Comparison groups |
Trastuzumab Emtansine 3.6 mg + Placebo v Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||||||||||||
Number of subjects included in analysis |
9
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[5] | ||||||||||||
P-value |
= 0.7175 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.35
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.27 | ||||||||||||
upper limit |
6.81 | ||||||||||||
Notes [5] - Stratified Analysis: Local hormonal status (ER and/or PgR positive vs. ER and PgR negative/unknown) and Disease status (visceral metastasis without brain metastasis vs. non-visceral metastasis only without brain metastasis [including locally advanced disease] vs. Brain metastasis). |
|
|||||||||||||
End point title |
OS in Participants with Baseline Brain Metastases | ||||||||||||
End point description |
OS is defined as the time from the first dose of study treatment to the time of death from any cause. Median OS was calculated using the KM methodology. ITT with brain metastasis population included all participants in ITT with brain metastasis at randomization. 99999= median and 95%CI was not estimable due to insufficient number of events. 9999= median and upper limit of 95%CI was not estimable due to insufficient number of events.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Atezolizumab vs Placebo | ||||||||||||
Comparison groups |
Trastuzumab Emtansine 3.6 mg + Placebo v Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||||||||||||
Number of subjects included in analysis |
9
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[6] | ||||||||||||
P-value |
= 0.3173 [7] | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
999.99
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0 | ||||||||||||
upper limit |
9999 | ||||||||||||
Notes [6] - Stratified Analysis: Local hormonal status (ER and/or PgR positive vs. ER and PgR negative/unknown) and Disease status (visceral metastasis without brain metastasis vs. non-visceral metastasis only without brain metastasis [including locally advanced disease] vs. Brain metastasis). [7] - The upper limit of the 95 % CI was not estimable due to the insufficient number of events. |
|
|||||||||||||
End point title |
Central Nervous System (CNS) PFS as Determined by Investigator Using RECIST v1.1 in Participants With Baseline CNS Metastases | ||||||||||||
End point description |
CNS PFS=time from randomization to first occurrence of documented CNS PD/first occurrence of symptomatic CNS disease as determined by investigator according to RECIST v1.1 or death from any cause whichever occurs first. PD = at least a 20% increase in SOD of target lesions, taking as reference the smallest sum in study, including baseline, in addition to relative increase of 20%, sum must also demonstrate an absolute increase of ≥5 mm. Median PFS was calculated using KM methodology. Participants who experienced non-CNS PD at time of analysis were censored at date of this progression. Participants who experienced no PD & were alive at time of analysis were censored at date of their last post-baseline tumor assessment or, if they had no post-baseline tumor assessment, on date of randomization+1 day. ITT with CNS metastasis population=all participants in ITT with CNS metastasis at randomization. 99999=upper limit of 95% CI was not estimable due to insufficient number of events.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Atezolizumab vs Placebo | ||||||||||||
Comparison groups |
Trastuzumab Emtansine 3.6 mg + Placebo v Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||||||||||||
Number of subjects included in analysis |
11
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[8] | ||||||||||||
P-value |
= 0.8658 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.19
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.16 | ||||||||||||
upper limit |
8.6 | ||||||||||||
Notes [8] - Stratified Analysis: Local hormonal status (ER and/or PgR positive vs. ER and PgR negative/unknown) and Disease status (visceral metastasis without brain metastasis vs. non-visceral metastasis only without brain metastasis [including locally advanced disease] vs. Brain metastasis). |
|
|||||||||||||
End point title |
Percentage of Participants with Adverse Events (AEs) [9] | ||||||||||||
End point description |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Safety evaluable population included all participants who received at least one full or partial dose of study drug. One participant randomized to Trastuzumab Emtansine + Placebo moved to Trastuzumab Emtansine + Atezolizumab 1200 mg. Hence, has been represented in the later arm for safety analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
Notes [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: All analysis was descriptive only and no formal hypothesis testing was done. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
CNS PFS as Determined by Investigator Using RECIST v1.1 in Participants Without Baseline CNS Metastases | ||||||||||||
End point description |
CNS PFS=time from randomization to first occurrence of documented CNS PD/first occurrence of symptomatic CNS disease as determined by investigator according to RECIST v1.1 or death from any cause whichever occurs first. PD=at least a 20% increase in SOD of target lesions, taking as reference the smallest sum in study, including baseline, in addition to relative increase of 20%, sum must also demonstrate an absolute increase of ≥5 mm. Participants who experienced non-CNS PD at time of analysis were censored at date of this progression. Participants who experienced no PD & were alive at time of analysis were censored at last post-baseline (PB) tumor assessment or on date of randomization+1 day (if no PB data). ITT without CNS metastases at baseline population=all participants in ITT without CNS metastasis at baseline. 9999=median & 95% CI were not estimable due to insufficient number of events. 999=median & upper limit of 95% CI were not estimable due to insufficient number of events.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Atezolizumab vs Placebo | ||||||||||||
Statistical analysis description |
Stratified Analysis: Local hormonal status (ER and/or PgR positive vs. ER and PgR negative/unknown) and Disease status (visceral metastasis without brain metastasis vs. non-visceral metastasis only without brain metastasis [including locally advanced disease] vs. Brain metastasis).
|
||||||||||||
Comparison groups |
Trastuzumab Emtansine 3.6 mg + Placebo v Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
||||||||||||
Number of subjects included in analysis |
85
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.8407 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.16
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.27 | ||||||||||||
upper limit |
4.99 |
|
|||||||||||||
End point title |
Mean Absolute Scores in Physical Function (PF), Role Function (RF) and Global Health Status (GHS/QoL) Scores Measured Using European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) | ||||||||||||
End point description |
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), GHS/QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The PF scale has 5 questions about participant’s PF and daily activities (strenuous activities, long walks, short walks, bed/chair rest & needing help with eating, dressing, washing themselves, or using the toilet). The RF scale has 2 questions about work/daily activities and hobbies/leisurely activities. The PF and RF are scored on a 4-point scale (1=Not at All to 4=Very Much). The GHS/QoL are scored on a 7-point scale (1=Very Poor to 7=Excellent). The obtained scores are linearly transformed to a score range of 0-100, where higher scores indicate a higher response level and better QoL, functioning/support.
|
||||||||||||
End point type |
Other pre-specified
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Notes [10] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. [11] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PFS as Determined by a Blinded Independent Central Review (BICR) Committee Using RECIST v1.1 | ||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of documented PD, as determined by the BICR committee according to RECIST v1.1 or death from any cause whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. As prespecified in the latest protocol, following sponsor’s decision to prematurely terminate the study, analysis of PFS as determined by a BICR committee was not conducted.
|
||||||||||||
End point type |
Other pre-specified
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Notes [12] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. [13] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change From-Baseline in PF, RF and GHS/QoL Scores Measured Using EORTC QLQ-C30 | ||||||||||||
End point description |
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), GHS/QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).The PF scale has 5 questions about participant’s PF and daily activities (strenuous activities, long walks, short walks, bed/chair rest & needing help with eating, dressing, washing themselves, or using the toilet). The RF scale has 2 questions about work/daily activities and hobbies/leisurely activities. The PF and RF are scored on a 4-point scale (1=Not at All to 4=Very Much). The GHS/QoL are scored on a 7-point scale (1=Very Poor to 7=Excellent). The obtained scores are linearly transformed to a score range of 0-100, where higher scores indicate a higher response level and better QoL, functioning/support.
|
||||||||||||
End point type |
Other pre-specified
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Notes [14] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. [15] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Maximum Serum Concentration (Cmax) of Trastuzumab Emtansine | ||||||||||||
End point description |
As prespecified in the latest protocol, following sponsor’s decision to prematurely terminate the study, pharmacokinetic (PK) objectives and outcome measures were no longer applicable. Hence sample collection was stopped, and this outcome measure was not assessed or analyzed.
|
||||||||||||
End point type |
Other pre-specified
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Notes [16] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. [17] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. |
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of Participants with Clinically Meaningful Deterioration in PF, RF and GHS/QoL Measured Using EORTC QLQ-C30 | |||||||||
End point description |
EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), GHS/QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).The PF scale has 5 questions about participant’s PF and daily activities (strenuous activities, long walks, short walks, bed/chair rest & needing help with eating, dressing, washing themselves, or using the toilet). The RF scale has 2 questions about work/daily activities and hobbies/leisurely activities. The PF and RF are scored on a 4-point scale (1=Not at All to 4=Very Much). The GHS/QoL are scored on a 7-point scale (1=Very Poor to 7=Excellent). The obtained scores are linearly transformed to a score range of 0-100, where higher scores indicate a higher response level and better QoL, functioning/support.
|
|||||||||
End point type |
Other pre-specified
|
|||||||||
End point timeframe |
Up to 28 months
|
|||||||||
|
||||||||||
Notes [18] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. [19] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. |
||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Cmax of Atezolizumab | ||||||||||||
End point description |
As prespecified in the latest protocol, following sponsor’s decision to prematurely terminate the study, PK objectives and outcome measures were no longer applicable. Hence sample collection was stopped, and this outcome measure was not assessed or analyzed.
|
||||||||||||
End point type |
Other pre-specified
|
||||||||||||
End point timeframe |
Up to 28 months
|
||||||||||||
|
|||||||||||||
Notes [20] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. [21] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. |
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Trastuzumab Emtansine | |||||||||
End point description |
As prespecified in the latest protocol, following sponsor’s decision to prematurely terminate the study, immunogenicity objectives and outcome measures were no longer applicable. Hence sample collection was stopped, and this outcome measure was not assessed or analyzed.
|
|||||||||
End point type |
Other pre-specified
|
|||||||||
End point timeframe |
Up to 28 months
|
|||||||||
|
||||||||||
Notes [22] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. [23] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of Participants With ADAs to Atezolizumab | |||||||||
End point description |
As prespecified in the latest protocol, following sponsor’s decision to prematurely terminate the study, immunogenicity objectives and outcome measures were no longer applicable. Hence sample collection was stopped, and this outcome measure was not assessed or analyzed.
|
|||||||||
End point type |
Other pre-specified
|
|||||||||
End point timeframe |
Up to 28 months
|
|||||||||
|
||||||||||
Notes [24] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. [25] - Sponsor prematurely terminated the study, and hence analysis of this endpoint was not conducted. |
||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 28 months
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Safety evaluable population included all participants who received at least one full or partial dose of study drug. One participant randomized to Trastuzumab Emtansine + Placebo moved to Trastuzumab Emtansine + Atezolizumab 1200 mg. Hence, has been represented in the later arm for safety analysis.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
27.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received trastuzumab emtansine, 3.6 mg, Q3W as an IV infusion in combination with atezolizumab, 1200 mg, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Trastuzumab Emtansine 3.6 mg + Placebo
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received trastuzumab emtansine, 3.6 mg, Q3W as an IV infusion in combination with atezolizumab matching placebo, Q3W as an IV infusion on Day 1 of each 21-day cycle until radiographic disease progression, intolerable toxicity, withdrawal of consent, death or study termination by the sponsor. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
15 Mar 2021 |
1. Updated to clarify that the independent Data Monitoring Committee reviewed safety data and efficacy data.
2. Inclusion and exclusion criteria were updated.
3. Updated the number of times that the NCI PRO-CTCAE patient-reported outcome questionnaire will be administered during cycles 1, 2, and 3 [from twice (Days 1 and 15) to three times (Days 1, 8, and 15)].
4. The Schedule of Assessments has been updated to introduce additional visits for safety assessments on Day 10 (±3 days) of Cycle 1 and Cycle 2. |
||||||
22 Feb 2022 |
1. Increased the window for prescreening testing from 6 months to 12 months, and revised that up to two prescreening samples can be
sent for analysis
2. Updated to provide guidance for HER2 and PD-L1 assessment in participants with initially multicentric tumors (multiple tumors involving
more than one quadrant) or multifocal tumors (more than one mass confined to the same quadrant as the primary tumor).
3. Clarified that the use of hormonal contraceptives and hormone releasing intrauterine devices are prohibited in women with hormone receptor-positive tumors.
4. Updated to add a time window (+/- 10 minutes) for the infusions of trastuzumab emtansine, and guidance on the premedications that can be used for the second and subsequent infusions of trastuzumab emtansine have been added |
||||||
02 Mar 2023 |
1. Revisions have been made to the study objectives to indicate which objectives are no longer applicable and the corresponding analyses that were no longer be performed.
2. The end of study and length of study have been updated.
3. The planned analyses for both PFS and OS in the context of the premature study termination have been clarified, as well as the impact of the premature study termination on the study sample size. |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
The Sponsor decided to prematurely terminate the study due to a lower-than-expected enrollment rate. |